NCI-H295R Human Adrenocortical Adenocarcinoma Cell

Multiangular, adherent growth This cell line is derived from the pluripotent adrenocortical carcinoma cell line NCI-H295, which was established by GazdarAF and was isolated from adrenal cortical tumors. NCI-295R cells were obtained by changing the culture conditions of NCI-H295 cells, and the population doubling time was reduced from 5 days to 2 days. NCI-295 cells grew in suspension, while NCI-H295R grew in monolayer. NCI-H295R cells retain the ability to produce androgens and react to angiotensin II and potassium ions. It was identified as free of mycoplasma/STR and put into storage.

Animal species/Organism Human

Tissue and Cell Type adrenal gland, cortical adenocarcinoma

Morphology epithelial cell-like, adherent growth

Culture media and additives/Complete Growth Medium and Culture Conditions:

DMEM/F12(1:1): Ham＇s F12/DME Medium (DME H-16/F-12 50% Mixture w/o HEPES, with NEAA Medium) Nu-Serum I, 2.5%； 15 mM HEPES(SD0009)＋0.00625 mg/ml insulin(SD0020)＋0.00625 mg/ml transferrin＋6.25 ng/ml selenium＋1.25 mg/ml bovine serum albumin＋0.00535 mg/ml linoleic acid

Gas phase: air, 95%; Carbon dioxide, 5%. Temperature: 37 ℃.

Freezing conditions: basic medium+5% DMSO+20% FBS (SD0200)

Complete cryopreservation solution: non-programmed cooling cell cryopreservation solution (low serum) (SD0001)

Note: This product is for scientific research only

PubMed=15541570; DOI=10.1016/j.mce.2003.12.020

Rainey W.E., Saner K., Schimmer B.P.

Adrenocortical cell lines.

Mol. Cell. Endocrinol. 228:23-38(2004)

PubMed=18000308; DOI=10.1677/JOE-07-0166

Samandari E., Kempna P., Nuoffer J.M., Hofer G., Mullis P.E., Fluck C.E.

Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3beta-hydroxysteroid dehydrogenase type 2 and 17,20 lyase activities.

J. Endocrinol. 195:459-472(2007)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=21924324; DOI=10.1016/j.mce.2011.08.041

Wang T., Rainey W.E.

Human adrenocortical carcinoma cell lines.

Mol. Cell. Endocrinol. 351:58-65(2012)

PubMed=22266826; DOI=10.1055/s-0031-1298019

Wang T., Rowland J.G., Parmar J., Nesterova M., Seki T., Rainey W.E.

Comparison of aldosterone production among human adrenocortical cell lines.

Horm. Metab. Res. 44:245-250(2012)

PubMed=23951072; DOI=10.1371/journal.pone.0071022

Nishi H., Arai H., Momiyama T.

NCI-H295R, a human adrenal cortex-derived cell line, expresses purinergic receptors linked to Ca(2)(+)-mobilization/influx and cortisol secretion.

PLoS ONE 8:E71022-E71022(2013)

PubMed=29371329; DOI=10.1530/ERC-17-0447

Kiseljak-Vassiliades K., Zhang Y., Bagby S.M., Kar A., Pozdeyev N., Xu M., Gowan K., Sharma V., Raeburn C.D., Albuja-Cruz M., Jones K.L., Fishbein L., Schweppe R.E., Somerset H.L., Pitts T.M., Leong S., Wierman M.E.

Development of new preclinical models to advance adrenocortical carcinoma research.

Endocr. Relat. Cancer 25:437-451(2018)